SCHEMBL1929102

SCHEMBL1929102

CCCC[Si](O[C@@H](C)C(=O)O)(c1ccccc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
GAA P10253 1/20 0.37
PKM P14618 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
RECQL P46063 1/20 0.36
ALDH1A1 P00352 2/20 0.36
NAAA Q02083 3/20 0.36
POLB P06746 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 3/20 0.35
CES2 O00748 2/20 0.35
CES1 P23141 2/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1929104 1.00 KMT2A (0.37) KMT2ACYP1A2CYP2C9CYP2C19GAA
SCHEMBL9847657 0.80 NAAA (0.36) CYP1A2CYP2C9CYP2C19GAAALDH1A1
SCHEMBL9504610 0.80 LTA4H (0.33) ALDH1A1POLBTSHR
SCHEMBL9296437 0.77 ALDH1A1 (0.35) KDM4EALDH1A1NAAAPOLBNPC1
SCHEMBL6554058 0.76 PTGS2 (0.39) ALDH1A1NAAATSHRCES2CES1
SCHEMBL22013347 0.76 LTA4H (0.30) NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6555698 0.75 ALDH1A1 (0.36) KMT2AKDM4EMEN1RECQLALDH1A1
SCHEMBL6554056 0.75 NAAA (0.37) KMT2AKDM4EMEN1RECQLALDH1A1
SCHEMBL875722 0.75 LTA4H (0.38) CYP1A2CYP2C9CYP2C19NAAATSHR
SCHEMBL9295317 0.74 KDM4E (0.47) KMT2AKDM4EMEN1RECQLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956073-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2011-06-07 US disclosed
US-20080182992-A1 Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents ARRAY BIOPHARMA, INC. 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182992-A1 Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents KIF5B, KIF2C, KIFC1 KMT2A 845/4885CYP1A2 4542/4885CYP2C9 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.